Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
The purpose of this study is to collect information on what effects (good or bad) CT-2103 (Xyotax) has on breast cancer as well as any side effects the drug may cause.
Breast Cancer|Metastatic Breast Cancer
DRUG: CT-2103 (Xyotax)
To evaluate the response to CT02103 as first or second-line treatment in patients with metastatic breast cancer.
To evaluate the side effects of CT-2103 in patients with metastatic breast cancer|to evaluate the proportion of patients that have complete or partial response or stable disease at 4 months|to determine the time to progression and overall survival of patients treated with CT2103.
* Patients will be given CT-2103 intravenously every 3 weeks. One week after the first dose of CT-2103 a physical exam, blood work and assessment of any side effects will be performed.
* Prior to each injection of CT-2103, a physical exam, blood work and assessment of any side effects will be performed (every 3 weeks).
* Every 6 weeks the patient's cancer will be re-evaluated with either a CT scan or MRI to determine whether the treatment is working.
* Additional blood work will be performed once per week after the first two doses of CT-2103.
* The participation in this study will last at least 2 cycles (6 weeks), however patients may remain on the study as long as there is no disease progression, and they are able to tolerate the study drug without severe side effects.